CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 697 enrolled
Drug / intervention
tanezumab +3 morebiological
Likely dose
tanezumab 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00733902
NCT00733902Phase 3Completed
CompareCT.gov

A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF TANEZUMAB IN PATIENTS WITH OSTEOARTHRITIS OF THE KNEE

Pfizer·interventional·Posted Aug 13, 2008·Updated Mar 22, 2021

In Brief

A Phase 3 clinical trial evaluating tanezumab and Placebo for Arthritis and Osteoarthritis. Completed, enrolled 697 participants across 82 sites.

Detailed Summary

Test the efficacy and safety of 3 doses in Osteoarthritis of the knee in patients.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsArthritis, Osteoarthritis
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedAug 13, 2008
Enrollment StartSep 15, 2008
Primary CompletionAug 24, 2009
Study CompletionJan 14, 2010
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 17.9 years ago

Interventions

tanezumabbiological

IV tanezumab 10 mg at 1 dose every 8 weeks

tanezumabbiological

IV tanezumab 5 mg at 1 dose every 8 weeks

tanezumabbiological

IV tanezumab 2.5 mg at 1 dose every 8 weeks

Placebobiological

IV placebo to match tanezumab at 1 dose every 8 weeks